Published September 27, 2023 | Version v1

A Review On Omaveloxolone

Description

Omaveloxolone is a semisynthetic triterpenoid used to treat friedreich’s ataxia. It is the second generation oleananetriterpenoid Nrf2 inducer with antioxidant and anti-inflammatory properties. It is currently used to test in medical trials for freidreich’s ataxia, a genetic, multi –organ disease involving mitochondrial dysfunction. It is a nuclear factor erythroid 2 related factor 2 (Nrf2) activator. It is reviewed under Food and Drug Administration and it has the potential to first approved treatment for friedreich’s ataxia. Omaveloxolone is not the cure for friedreich’s ataxia, it is the first agent targeting to reach NDA submission. It is the rational and potent therapy that is probably disease modifying in the treatment of friedreich’s ataxia. Omaveloxolone (RTA-408) is an Nrf2 activator, which decreases the susceptibility of cells through oxidative stress and it leads to cell death and tissue degradation. It is good tolerated not having any significant long term adverse effects. Treatment with RTA-408 remarkably improved in the neurological function, it is measured by modified Freidreich’s Ataxia Rating Scale.

Files

45_Lalitha A_vol_1_issue_9_2023.pdf

Files (279.6 kB)

Name Size
md5:b889935d414a84b22fa97c88e3cae0e2
279.6 kB Preview Download